Paul Audhya compensation by year
KalVista Pharmaceuticals Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $502,900 | $502,900 | $523,016 |
| Bonus | $221,276 | $221,276 | $313,810 |
| Stock awards | $1,097,159 | $1,097,159 | $1,938,200 |
| Option awards | $0 | $0 | $0 |
| Non-equity incentive | — | $0 | $0 |
| Pension and deferred compensation | — | $0 | $0 |
| All other | $12,639 | $12,639 | $14,068 |
| Total | $1,833,974 | $1,833,974 | $2,789,094 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: KalVista Pharmaceuticals, Inc. 10-KT/A filed April 30, 2026, accession 0001193125-26-197556, and prior-year filings. Open the filing on EDGAR.
How this page was built: the KalVista Pharmaceuticals, Inc. filed document, accession 0001193125-26-197556. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 81,250 | $814,938 | — |
| RSU | 50,000 | $584,500 | — |
| RSU | 4,838 | $44,897 | — |
| Option | 2,688 | — | $9.28 |
Per the Outstanding Equity Awards at Fiscal Year-End table in KalVista Pharmaceuticals, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
15 Form 4 lines since the FY2024 proxy (filed April 30, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-06-11 | Disposition to the issuer derivative | — | 68,750 | — | 0 |
| 2026-06-11 | Disposition to the issuer derivative | — | 93,750 | — | 0 |
| 2026-06-11 | Disposition to the issuer derivative | — | 25,800 | — | 0 |
| 2026-06-11 | Disposition to the issuer | — | 150,260 | $0.00 | 0 |
| 2026-06-11 | Disposition to the issuer derivative | — | 40,000 | — | 0 |
| 2026-06-11 | Disposition to the issuer derivative | — | 100,000 | — | 0 |
| 2026-05-26 | Sale | — | 2,239 | $26.78 | 150,260 |
| 2026-05-22 | Exercise or conversion | — | 5,000 | — | 152,499 |
The 8 most recent of 15 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
KalVista Pharmaceuticals’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Benjamin Palleiko | Chief Executive Officer | $6,772,197 |
| Paul Audhya · this page | Chief Medical Officer | $1,833,974 |
The full KalVista Pharmaceuticals compensation record
free company briefThis page is one person within KalVista Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order KalVista Pharmaceuticals's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are KalVista Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order KALV
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.